Astra Invests $3.5 Billion in US
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but ...
Hosted on MSN2d
AstraZeneca Expands U.S. Investment PlanAstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback